Comparative Pharmacology
Head-to-head clinical analysis: FLOVENT DISKUS 50 versus WIXELA INHUB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOVENT DISKUS 50 versus WIXELA INHUB.
FLOVENT DISKUS 50 vs WIXELA INHUB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; anti-inflammatory transcription factor modulation; inhibits phospholipase A2, reduces arachidonic acid release, decreases prostaglandin and leukotriene synthesis; suppresses cytokine production and inflammatory cell migration.
Wixela Inhub is an inhaled corticosteroid (fluticasone propionate) and long-acting beta2-adrenergic agonist (salmeterol) combination. Fluticasone propionate reduces inflammation by binding to glucocorticoid receptors, inhibiting pro-inflammatory mediators. Salmeterol stimulates beta2-receptors in bronchial smooth muscle, leading to bronchodilation via activation of adenylate cyclase and increased cAMP.
1 inhalation (50 mcg) twice daily, administered via oral inhalation.
2 inhalations (total dose 50 mcg indacaterol/110 mcg glycopyrrolate) once daily via oral inhalation.
None Documented
None Documented
Terminal elimination half-life is approximately 14-17.5 hours; this supports once- or twice-daily dosing in asthma maintenance.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged (up to 30-50 hours) in renal impairment.
Primarily fecal (87-90%) after hepatic metabolism; renal excretion accounts for <5% as unchanged drug and metabolites.
Primarily renal excretion (70-80%) as unchanged drug; biliary/fecal (20-30%) as parent and metabolites.
Category C
Category C
Corticosteroid
Corticosteroid/LABA Combination